Dynavax Technologies
Corporation DVAX and AstraZeneca announced today their
decision to advance AZD1419, a proprietary second-generation TLR-9
agonist for asthma, into IND-enabling preclinical toxicology studies.
These toxicology studies are scheduled to be the first module of work
performed by Dynavax under the recently amended collaboration
agreement for the clinical development of AZD1419. Development
expenses will be fully funded by AstraZeneca, and Dynavax will
receive payment of $2.6 million to begin the studies.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in